tirzepatide cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized 🫀 EASD 2025: Tirzepatide (SURPASS-CVOT)

The sulfhydryl group (SH) of the cysteine is involved in reduction and conjugation reactions that are usually considered as the most important functions of GSH

Kidney of rats fed on 30% chocolate

Given that PKC signaling pathway is also significantly downregulated in GPR146 knockdown cells from our phosphoproteomics study, we next tested whether GPR146 regulates adipogenesis by coupling to Gq

7 Validates patient daytime phone number and extension formatting Ensures the Patient preferred daytime phone number includes a valid North American numbering plan format (10 digits, allowing separators) and that the extension (if provided) is numeric and within a reasonable length